{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:09:18Z","timestamp":1761174558313,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["ISCIII-RETIC RD06\/006","PI12\/01053"],"award-info":[{"award-number":["ISCIII-RETIC RD06\/006","PI12\/01053"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.cmi.2014.08.005","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T14:11:48Z","timestamp":1419257508000},"page":"104.e1-104.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults"],"prefix":"10.1016","volume":"21","author":[{"given":"M.","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Monge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Chueca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Anta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Gomez-Sirvent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. de los","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.cmi.2014.08.005_bib1","first-page":"6","article-title":"Update of the drug resistance mutations in HIV-1","volume":"2013","author":"Johnson","year":"2013","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.cmi.2014.08.005_bib2","doi-asserted-by":"crossref","first-page":"e33484","DOI":"10.1371\/journal.pone.0033484","article-title":"Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003\u20132010","volume":"7","author":"Karlsson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2014.08.005_bib3","doi-asserted-by":"crossref","first-page":"e12718","DOI":"10.1371\/journal.pone.0012718","article-title":"Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort","volume":"5","author":"Bartmeyer","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2014.08.005_bib4","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/644505","article-title":"Transmission of drug-resistant human immunodeficiency virus type 1 is stabilizing in Europe","volume":"200","author":"Vercauteren","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2014.08.005_bib5","first-page":"673","article-title":"Transmitted antiretroviral drug resistance among acute and recent human immunodeficiency virus infections in North Carolina from 1998 to 2007","volume":"14","author":"Hurt","year":"2009","journal-title":"AntivirTher"},{"key":"10.1016\/j.cmi.2014.08.005_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP2358","article-title":"Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response","volume":"18","author":"Vingerhoets","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2014.08.005_bib7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/jac\/dkt003","article-title":"Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses","volume":"68","author":"Lambert-Niclot","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2014.08.005_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0213-005X(13)70141-1","article-title":"[Resistance profile of rilpivirine]","volume":"31","author":"Imaz","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.cmi.2014.08.005_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2011.05.010","article-title":"Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment na\u00efve HIV-infected individuals (CoRIS)","volume":"91","author":"Garc\u00eda","year":"2011","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2014.08.005_bib10","doi-asserted-by":"crossref","first-page":"E485","DOI":"10.1111\/1469-0691.12011","article-title":"Analysis of transmitted drug resistance in Spain in the years 2007\u20132010 documents a decline in mutations to the non-nucleoside drug class","volume":"18","author":"Monge","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.cmi.2014.08.005_bib11","doi-asserted-by":"crossref","first-page":"e90710","DOI":"10.1371\/journal.pone.0090710","article-title":"Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations","volume":"9","author":"Monge","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2014.08.005_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1157\/13096749","article-title":"Spanish cohort of na\u00efve human immunodeficiency virus infected patients (CoRIS): rationale, organization and initial results","volume":"25","author":"Caro-Murillo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.cmi.2014.08.005_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eimc.2011.06.002","article-title":"The cohort of the Spanish HIV research network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up","volume":"29","author":"Sobrino-Vegas","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.cmi.2014.08.005_bib14","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web Resources for HIV type 1 Genotypic-Resistance Test Interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2014.08.005_bib15","series-title":"Prevalence of mutations and determinants of genotypic resistance to rilpivirine in B and the most prevalent non-B HIV-1 subtypes in Italy","first-page":"19","author":"Santoro","year":"2013"},{"key":"10.1016\/j.cmi.2014.08.005_bib16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"ECHO Study Group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-na\u00efve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2014.08.005_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2014.08.005_bib18","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1128\/AAC.00348-13","article-title":"Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine","volume":"57","author":"Xu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2014.08.005_bib19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/QAD.0b013e32835d9f6d","article-title":"Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline","volume":"27","author":"Asahchop","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2014.08.005_bib20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/cid\/cit430","article-title":"Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity","volume":"57","author":"Gatanaga","year":"2013","journal-title":"Clin Infect Dis"},{"year":"2013","author":"Camacho","series-title":"Algorithm for the use of genotypic HIV-1 resistance data (version Rega v9.1.0)","key":"10.1016\/j.cmi.2014.08.005_bib21"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:11:43Z","timestamp":1761117103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1198743X14000123"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2014.08.005","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2014.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}